Free tool
FAERS Monitor: Vafseo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215192 or its brand name (Vafseo, Vadadustat). Reports on generic versions are filed under their own applications.
Reports
307
Serious
267
87% of reports
Hospitalization
108
Death reported
96
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea30
- haemoglobin decreased20
- off label use20
- death17
- cardiac failure14
- marasmus14
- nausea13
- drug interaction12
- pneumonia11
- cardiac failure congestive9
- haemoglobin increased9
- rhabdomyolysis9
- cardiac failure chronic8
- dialysis8
- pneumonia aspiration8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 14 |
| 2023 | 27 |
| 2024 | 133 |
| 2025 | 55 |
| 2026 | 69 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,852 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| marasmusSignal | 14 | 637.1 | 381.0 | 8,191 |
| haemoglobin increasedSignal | 9 | 135.4 | 71.1 | 1,068 |
| cardiac failure chronicSignal | 8 | 128.8 | 65.0 | 890 |
| dialysisSignal | 8 | 38.6 | 19.5 | 257 |
| pneumonia aspirationSignal | 8 | 21.9 | 11.1 | 140 |
| rhabdomyolysisSignal | 9 | 14.8 | 7.8 | 103 |
| haemoglobin decreasedSignal | 20 | 13.3 | 8.7 | 217 |
| cardiac failureSignal | 14 | 11.9 | 7.2 | 130 |
| cardiac failure congestiveSignal | 9 | 7.7 | 4.0 | 46 |
| drug interactionSignal | 12 | 5.2 | 3.0 | 37 |
| diarrhoeaSignal | 30 | 3.2 | 2.3 | 44 |
| pneumoniaSignal | 11 | 2.3 | 1.3 | 7 |
| off label use | 20 | 1.6 | 1.0 | 4 |
| death | 17 | 1.4 | 0.9 | 1 |
| nausea | 13 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.